Lehrstuhl für Geburtshilfe und Frauenheilkunde

Management of Uterus bicornis unicollis with a right-sided Outflow Obstruction in a 13-year-old Girl (2020) Lubrich H, Pontones C, Koch M, Fahlbusch C, Oppelt P, Beckmann M Conference contribution Preconceptual Counseling, Prenatal Care and peripartum Management of Female Patients with Ullrich-Turner Syndrome and a High-risk cardiovascular Profile (2020) Pontones C, Lubrich H, Schwenke E, Cupisti S, Dittrich R, Kehl S, Beckmann M, et al. Conference contribution Mammographic Density and Prognosis in Patients with primary Breast Cancer - Loss of Risk with increasing Age (2020) Heindl F, Fasching P, Hein A, Hack C, Heusinger K, Gaß P, Schulz-Wendtland R, et al. Conference contribution Influence of mindfulness-based Stress Reduction on Patients with Endometriosis in a randomized Cohort Study (2020) Antoniadis S, Burghaus S, Becker K, Beckmann M, Hack C Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article Influence of CDK4/6 inhibitors on the peripheral immune response in hormone receptor-positive breast cancer (2020) Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Hennig S, Schaper S, Brucker S, et al. Conference contribution Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) Schmidt M, Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, et al. Journal article Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, et al. Journal article Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres (2020) Hester A, Gaß P, Fasching P, Kraemer AK, Ettl J, Diessner J, Woeckel A, et al. Journal article Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution